Impact of duration of symptoms prior to first hospitalization on acute outcome in 998 schizophrenic patients

Schizophrenia Research

Volumn 44, Issue 2, 2000, Pages 145-150

  Bottlender, Ronald ^a   Strauß, Anton ^a   Möller, Hans Jürgen ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Response; Schizophrenia; Treatment

Indexed keywords

ADULT; ARTICLE; DOCUMENTATION; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEGATIVE SYNDROME; OUTCOMES RESEARCH; PRIORITY JOURNAL; SCHIZOPHRENIA; SYMPTOM;

ACUTE DISEASE; ADULT; DISEASE PROGRESSION; FEMALE; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; PATIENT ADMISSION; PROSPECTIVE STUDIES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 0343627982     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(99)00186-3     Document Type: Article

References (17)

1. Altamura A.C. A multidimensional pharmacokinetic and clinical-biological approach to neuroleptic response in schizophrenia. With particular reference to drug resistance. Schizophr. Res. 8:(3):1993;187-198.
2. Angermeyer M.C., Kuhn L., Goldstein J.M. Gender and the course of schizophrenia: differences in treated outcomes. Schizophr. Bull. 16:(2):1990;293-307.
3. Angst J., Stassen H.H., Woggon B. Effect of neuroleptics on positive and negative symptoms and the deficit state. Psychopharmacol. Berl. 99:(Suppl.):1989;41-46.
4. Bobon D. Foreign adaptations of the AMDP-System. Bobon D., Baumann U., Angst J., Helmchen H., Hippius H. AMDP-System in Pharamcopsychiatry. 1983;19-34 Karger, Basle.
5. Bobon D., Woggon B. The AMDP-System in clinical psychopharmacology. Br. J. Psychiatry. 148:1986;467-468.
6. DeLisi L.E. The significance of age of onset for schizophrenia. Schizophr. Bull. 18:(2):1992;209-215.
7. DeLisi L.E., Sakuma M., Tew W., Kushner M., Hoff A.L., Grimson R. Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res. 74:(3):1997;129-140.
8. Endicott J., Spitzer R.L., Fleiss J.L., Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch. Gen. Psychiatry. 33:(6):1976;766-771.
9. Lieberman J.A. Prediction of outcome in first-episode schizophrenia. J. Clin. Psychiatry. 54:(Suppl.):1993;13-17.
10. Lieberman J.A., Koreen A.R., Chakos M., Sheitman B., Woerner M., Alvir J.M., Bilder R. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J. Clin. Psychiatry. 57:(Suppl. 9):1996;5-9.
11. Loebel A.D., Lieberman J.A., Alvir J.M.J., Mayerhoff D.I., Geisler S.H., Szymanski S.R. Duration of psychosis and outcome in first-episode schizophrenia. Am. J. Psychiatry. 149:(9):1992;1183-1188.
12. McEvoy J.P., Schooler N.R., Wilson W.H. Predictors of therapeutic response to haloperidol in acute schizophrenia. Psychopharmacol. Bull. 27:(2):1991;97-101.
13. Möller H.J. Review: treatment of schizophrenia. State of the art. Eur. Arch. Psychiatry Clin. Neurosci. 246:(5):1996;229-234.
14. Pietzcker A., Gebhardt R., Strauss A., Stockel M., Langer C., Freudenthal K. The syndrome scales in the AMDP-system. Mod. Probl. Pharmacopsychiatry. 20:1983;88-99.
15. Pinals D.A., Malhotra A.K., Missar C.D., Pickar D., Breier A. Lack of gender differences in neuroleptic response in patients with schizophrenia. Schizophr. Res. 22:(3):1996;215-222.
16. Szymanski S., Lieberman J.A., Alvir J.M., Mayerhoff D., Loebel A., Geisler S., Chakos M., Koreen A., Jody D., Kane J. Gender differences in onset of illness treatment response course and biologic indexes in first-episode schizophrenic patients. Am. J. Psychiatry. 152:(5):1995;698-703.
17. Wyatt R.J. Neuroleptics and the natural course of schizophrenia. Schizophr. Bull. 17:(2):1991;325-351.